1. Home
  2. SMHI vs NGEN Comparison

SMHI vs NGEN Comparison

Compare SMHI & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SEACOR Marine Holdings Inc.

SMHI

SEACOR Marine Holdings Inc.

HOLD

Current Price

$8.35

Market Cap

212.7M

ML Signal

HOLD

NGEN

NervGen Pharma Corp. Common stock

N/A

Current Price

$1.69

Market Cap

197.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SMHI
NGEN
Founded
1989
2017
Country
United States
Canada
Employees
N/A
9
Industry
Marine Transportation
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
212.7M
197.5M
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
SMHI
NGEN
Price
$8.35
$1.69
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$18.00
AVG Volume (30 Days)
170.1K
833.4K
Earning Date
04-29-2026
04-02-2026
Dividend Yield
N/A
N/A
EPS Growth
62.41
N/A
EPS
N/A
N/A
Revenue
$173,783,000.00
N/A
Revenue This Year
$1.21
N/A
Revenue Next Year
$9.31
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.70
$1.70
52 Week High
$8.47
$5.93

Technical Indicators

Market Signals
Indicator
SMHI
NGEN
Relative Strength Index (RSI) 62.70 32.74
Support Level $6.89 N/A
Resistance Level N/A $2.28
Average True Range (ATR) 0.48 0.14
MACD 0.07 0.01
Stochastic Oscillator 88.73 0.93

Price Performance

Historical Comparison
SMHI
NGEN

About SMHI SEACOR Marine Holdings Inc.

Seacor Marine Holdings Inc provides marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that (i) deliver cargo and personnel to offshore installations, including offshore wind farms, (ii) assist offshore operations for production and storage facilities, (iii) provide construction, well work-over, offshore wind farm installation and decommissioning support and (iv) carry and launch equipment used underwater in drilling and well installation, maintenance, inspection and repair. Its geographical segment includes the United States (Gulf of Mexico), Africa and Europe, Middle East and Asia, and Latin America, with the majority of revenue deriving from the Africa and Europe segment.

About NGEN NervGen Pharma Corp. Common stock

NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.

Share on Social Networks: